Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Ovarian Neoplasms 39Breast Neoplasms 24Neoplasms 12Prostatic Neoplasms 11Triple Negative Breast Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Fanconi Anemia, Complementation Group D1 5Small Cell Lung Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Solid Tumors 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Colorectal Neoplasms 2Carcinoma 2Advanced Solid Tumours 2Advanced Solid Tumor 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Metastatic Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1

Interventions

adavosertib 5durvalumab 3Paclitaxel 3olaparib 2ceralasertib 2Fluorouracil 2Carboplatin 2toripalimab 1sintilimab 1factor IX, factor VII, factor X, prothrombin drug combination 1drug XX Z 1danvatirsen 1capivasertib 1Rifampin 1Omeprazole 1Leucovorin 1Itraconazole 1Irinotecan 1Gemcitabine 1Cisplatin 1AZD0156 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumours × olaparib × Clear all
NCT02588105 2022-09-19

AToM

AstraZeneca

Phase 1 Completed
84 enrolled
Other solid neoplasm

Advanced Solid Tumours

NCT02430311 2019-07-31

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

AstraZeneca

Phase 1 Completed
36 enrolled 24 charts
Other solid neoplasm

Advanced Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡